OBJ Limited (ASX: OBJ) is pleased to announce the signing of an Evaluation Agreement
with GlaxoSmithKline Consumer Healthcare (GSK). GSK has granted permission to the
Company to release the following statement:
OBJ Limited wishes to advise that it has entered into a short term evaluation
agreement with GlaxoSmithKline Consumer Healthcare (GSK).
The Evaluation Agreement involves an evaluation of OBJs ETP technology in a
non‐prescription consumer healthcare application.
OBJ and GSK have worked together on three previous occasions and the current
Agreement is a continuation of that relationship.
- Forums
- ASX - By Stock
- pre-open
OBJ Limited (ASX: OBJ) is pleased to announce the signing of an...
-
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
CXO
Core Lithium narrowly beats guidance on FY24 spodumene production but 1Y returns still shattered
FWD
Queensland's housing crisis an opportunity for ASX builder Fleetwood – and taxpayer cash a safe harbour from the storm
Add WFL (ASX) to my watchlist
|
|||||
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.478M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
WFL (ASX) Chart |
Day chart unavailable